Amgen receives CHMP positive opinion to add updated survival data to Kyprolis label

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amgen said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a label variation for Kyprolis (carfilzomib) to include updated overall survival data from the phase III head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (Kyprolis and dexamethasone versus Velcade [bortezomib] and dexamethasone).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login